Covid-19 Impact on Global Immunotherapy Drugs Market
Type: PDF
Status: Published
Categories: Pharma & Healthcare
Report Code : PHC214032
No. of Pages : 317
The global immunotherapy drugs market is expected to grow from USD 163.2 billion in 2020 to USD 381.5 billion by 2028 at a CAGR of 11.2 % over the forecast period 2021-2028.
Market Overview:
Immunotherapy drug is biologic therapy, which is a sort of cancer treatment. This treatment enhances the body's natural immunity to fight cancer. It utilizes biological substances to enhance system function by stopping cancer cells' expansion and helping the system figure better at destroying cancer cells. There are various types of immunotherapy available such as oncolytic virus therapy, monoclonal antibodies, non-specific immunotherapies, T-cell therapy, and cancer vaccines.
The global immunotherapy drug market is expected to grow due to driving factors like the rising prevalence of cancer worldwide and advancement within development techniques.
Market Dynamics:
Drivers:
Restraints:
Key Market Players:
Eli Lilly and Company, AstraZeneca, Abbvie, Amgen Inc, GlaxoSmithKline Plc, Novartis International AG, Merck, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, UbiVac are some of the prominent players in the global immunotherapy drugs market.
The market is segmented based on the below-mentioned segments:
On the Basis of Type: Revenue & Volume
o Monoclonal Antibodies
o Check Point Inhibitors
o Interferons
o Interleukins
On the Basis of Therapy Area: Revenue & Volume
o Cancer
o Autoimmune diseases & Inflammatory
o Infectious Diseases
On the Basis of End-User: Revenue & Volume
o Hospitals
o Clinics
On The Basis of Region: Revenue & Volume
Report Description
TABLE OF CONTENTS
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. SCOPE OF THE STUDY
1.3. GEOGRAPHIC SCOPE
1.4. MARKET DEFINITION
1.5. CURRENCY CONSIDERATION
1.6. YEAR CONSIDERATION
2. RESEARCH METHODOLOGY AND ASSUMPTIONS
2.1. SECONDARY RESEARCH
2.2. PRIMARY RESEARCH
2.3. MARKET BREAKUP AND DATA TRIANGULATION
2.4. MARKET SIZE ESTIMATION
2.4.1. BOTTOM UP APPROACH
2.4.2. TOP DOWN APPROACH
2.5. ASSUMPTION
3. EXECUTIVE SUMMARY
3.1. KEY MARKET INSIGHTS
3.2. SEGMENTATION OUTLOOK
3.3. COMPANY OUTLOOK
4. PREMIUM INSIGHTS
4.1. IMPACT OF COVID-19 ON MARKET
4.2. INDUSTRY ROAD MAP
4.3. INDUSTRY TREND
4.4. INDUSTRY SWOT ANALYSIS
4.5. MARKET ATTRACTIVENESS ANALYSIS
4.5.1. MARKET ATTRACTIVENESS BY SEGMENTS
4.5.1.1. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY TYPE
4.5.1.2. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY THERAPY AREA
4.5.1.3. IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY END-USER
4.5.2. MARKET ATTRACTIVENESS BY REGION
4.5.2.1. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.2. EUROPE IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.3. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.4. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.5.2.5. MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET ATTENTIVENESS BY COUNTRY
4.6. PORTER’S FIVE FORCES ANALYSIS
4.6.1. THREAT OF NEW ENTRANTS
4.6.2. THREAT OF SUBSTITUTES
4.6.3. BARGAINING POWER OF SUPPLIERS
4.6.4. BARGAINING POWER OF BUYERS
4.6.5. INTENSITY OF COMPETITIVE RIVALRY
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH & DEVELOPMENT COMPANIES
4.7.2. RAW MATERIAL/ COMPONENT SUPPLIERS
4.7.3. PRODUCT MANUFACTURERS
4.7.4. DISTRIBUTORS AND RETAILERS
4.7.5. END-USER INDUSTRIES
4.7.6. POST-SALES SERVICE PROVIDERS
4.8. FACTORS AFFECTING THE MARKET
4.8.1. MACRO FACTORS AFFECTING THE MARKET
4.8.2. MICRO FACTORS AFFECTING THE MARKET
4.8.3. PESTEL ANALYSIS
4.9. YEAR ON YEAR GROWTH RATE OF IMMUNOTHERAPY DRUGS
4.10. LIST OF SUPPLIERS
4.11. LIST OF BUYERS
4.12. COUNTRY LEVEL ANALYSIS
4.13. RULES AND REGULATION
5. MARKET DYNAMICS
5.1. MARKET DRIVERS
5.1.1. INCREASING CASES OF TARGET DISEASES
5.1.2. GROWING DEMAND FOR IMMUNOTHERAPY DRUGS OVER CONVENTIONAL TREATMENTS
5.2. MARKET RESTRAINTS
5.2.1. ISSUES RELATED TO SIDE-EFFECTS AND MANUFACTURING COMPLEXITIES
5.2.2. HIGH FRICTION RATE IN THE PRODUCT DEVELOPMENT CYCLE
5.3. MARKET OPPORTUNITIES
5.4. MARKET CHALLENGES
6. GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY TYPE - 2017-2028
6.1. KEY FINDINGS
6.2. MONOCLONAL ANTIBODIES
6.3. CHECK POINT INHIBITORS
6.4. INTERFERONS
6.5. INTERLEUKINS
7. GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY THERAPY AREA - 2017-2028
7.1. KEY FINDINGS
7.2. CANCER
7.3. AUTOIMMUNE DISEASES & INFLAMMATORY
7.4. INFECTIOUS DISEASES
8. GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY END-USER - 2017-2028
8.1. KEY FINDINGS
8.2. HOSPITALS
8.3. CLINICS
9. GLOBAL IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY REGIONAL - 2017-2028
9.1. KEY FINDINGS
9.2. NORTH AMERICA
9.3. EUROPE
9.4. ASIA PACIFIC
9.5. SOUTH AMERICA
9.6. MIDDLE EAST & AFRICA
10. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
10.1. BY COUNTRY
10.1.1. U.S.
10.1.2. CANADA
10.1.3. MEXICO
11. EUROPE IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
11.1. BY COUNTRY
11.1.1. GERMANY
11.1.2. U.K.
11.1.3. FRANCE
11.1.4. ITALY
11.1.5. SPAIN
11.1.6. SWEDEN
11.1.7. BELGIUM
11.1.8. TURKEY
11.1.9. RUSSIA
11.1.10. POLAND
11.1.11. SWITZERLAND
11.1.12. NETHERLANDS
11.1.13. REST OF EUROPE
12. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
12.1. BY COUNTRY
12.1.1.1. JAPAN
12.1.1.2. CHINA
12.1.1.3. INDIA
12.1.1.4. AUSTRALIA
12.1.1.5. SOUTH KOREA
12.1.1.6. MALAYSIA
12.1.1.7. INDONESIA
12.1.1.8. VIETNAM
12.1.1.9. NEW ZEALAND
12.1.1.10. PHILIPPINES
12.1.1.11. TAIWAN
12.1.1.12. SINGAPORE
12.1.1.13. REST OF ASIA-PACIFIC
13. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
13.1. BY COUNTRY
13.1.1.1. BRAZIL
13.1.1.2. ARGENTINA
13.1.1.3. CHILE
13.1.1.4. COLOMBIA
13.1.1.5. REST OF SOUTH AMERICA
14. MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET INSIGHTS AND FORECAST ANALYSIS, BY SEGMENTS AND COUNTRY - 2017-2028
14.1. BY COUNTRY
14.1.1.1. SOUTH AFRICA
14.1.1.2. U.A.E.
14.1.1.3. SAUDI ARABIA
14.1.1.4. REST OF MIDDLE EAST AND AFRICA
15. COMPETITIVE LANDSCAPE
15.1. MARKET SHARE OF KEY PLAYERS IN POWER TOOL MARKET
15.1.1. GLOBAL MARKET SHARE ANALYSIS
15.1.2. NORTH AMERICA MARKET SHARE ANALYSIS
15.1.3. EUROPE MARKET SHARE ANALYSIS
15.1.4. ASIA PACIFIC MARKET SHARE ANALYSIS
15.1.5. SOUTH AMERICA MARKET SHARE ANALYSIS
15.1.6. MIDDLE EAST & AFRICA MARKET SHARE ANALYSIS
15.2. LEADERSHIP MAPPING
15.2.1. VISIONARY PLAYERS
15.2.2. INNOVATORS PLAYERS
15.2.3. DYNAMIC DIFFERENTIATORS
15.2.4. EMERGING COMPANIES
15.3. COMPETITIVE SCENARIO AND TRENDS
15.3.1. MERGERS & ACQUISITIONS
15.3.2. PRODUCT LAUNCHES AND DEVELOPMENTS
15.3.3. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
15.3.4. EXPANSIONS
16. COMPANY PROFILES
16.1.1. ELI LILLY AND COMPANY
16.1.1.1. COMPANY OVERVIEW
16.1.1.2. COMPANY SNAPSHOT
16.1.1.3. FINANCIAL ANALYSIS
16.1.1.3.1. REVENUE ANALYSIS
16.1.1.3.2. SALES ANALYSIS
16.1.1.3.3. PRICE ANALYSIS
16.1.1.3.4. MARGIN ANALYSIS
16.1.1.4. GEOGRAPHICAL PRESENCE
16.1.1.4.1. NORTH AMERICA
16.1.1.4.2. EUROPE
16.1.1.4.3. ASIA PACIFIC
16.1.1.4.4. SOUTH AMERICA
16.1.1.4.5. MIDDLE EAST & AFRICA
16.1.1.5. PRODUCT PORTFOLIO
16.1.1.6. SWOT ANALYSIS
16.1.1.7. RECENT DEVELOPMENT
16.1.2. ASTRAZENECA
16.1.3. ABBVIE
16.1.4. AMGEN INC
16.1.5. GLAXOSMITHKLINE PLC
16.1.6. NOVARTIS INTERNATIONAL AG
16.1.7. MERCK
16.1.8. F. HOFFMANN-LA ROCHE AG
16.1.9. BRISTOL-MYERS SQUIBB
16.1.10. UBIVAC
17. STRATEGIC RECOMMENDATIONS
LIST OF TABLE
1. RESEARCH ASSUMPTION
2. COVID-19 IMPACT ON MARKET
3. MAJOR DEVELOPMENTS BY VARIOUS COMPANIES
4. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
5. GLOBAL MONOCLONAL ANTIBODIES IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
6. GLOBAL CHECK POINT INHIBITORS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
7. GLOBAL INTERFERONS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
8. GLOBAL INTERLEUKINS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
9. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
10. GLOBAL CANCER IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
11. GLOBAL AUTOIMMUNE DISEASES & INFLAMMATORY IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
12. GLOBAL INFECTIOUS DISEASES IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
13. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
14. GLOBAL HOSPITALS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
15. GLOBAL CLINICS IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2017–2028 REVENUE (USD MILLION)
16. GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY NORTH AMERICA, 2017–2028 REVENUE (USD MILLION)
17. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
18. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
19. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
20. U.S. IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
21. U.S. IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
22. U.S. IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
23. CANADA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
24. CANADA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
25. CANADA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
26. MEXICO IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
27. MEXICO IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
28. MEXICO IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
29. EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
30. EUROPE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
31. EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
32. GERMANY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
33. GERMANY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
34. GERMANY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
35. FRANCE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
36. FRANCE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
37. FRANCE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
38. U.K. IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
39. U.K. IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
40. U.K. IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
41. ITALY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
42. ITALY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
43. ITALY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
44. SPAIN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
45. SPAIN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
46. SPAIN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
47. SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
48. SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
49. SWEDEN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
50. BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
51. BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
52. BELGIUM IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
53. TURKEY IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
54. TURKEY IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
55. TURKEY IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
56. RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
57. RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
58. RUSSIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
59. POLAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
60. POLAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
61. POLAND IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
62. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
63. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
64. SWITZERLAND IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
65. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
66. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
67. NETHERLANDS IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
68. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
69. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
70. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
71. JAPAN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
72. JAPAN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
73. JAPAN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
74. CHINA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
75. CHINA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
76. CHINA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
77. INDIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
78. INDIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
79. INDIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
80. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
81. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
82. AUSTRALIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
83. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
84. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
85. SOUTH KOREA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
86. INDONESIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
87. INDONESIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
88. INDONESIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
89. VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
90. VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
91. VIETNAM IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
92. NEW ZEALAND IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
93. NEW ZEALAND IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
94. NEW ZEALAND IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
95. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
96. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
97. PHILIPPINES IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
98. TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
99. TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
100. TAIWAN IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
101. SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
102. SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
103. SINGAPORE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
104. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
105. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
106. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
107. BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
108. BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
109. BRAZIL IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
110. ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
111. ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
112. ARGENTINA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
113. CHILE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
114. CHILE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
115. CHILE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
116. COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
117. COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
118. COLOMBIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
119. MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
120. MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
121. MIDDLE EAST AND AFRICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
122. UAE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
123. UAE IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
124. UAE IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
125. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
126. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
127. SOUTH AFRICA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
128. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
129. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
130. SAUDI ARABIA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
131. REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, 2017–2028 REVENUE (USD MILLION)
132. REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2017–2028 REVENUE (USD MILLION)
133. REST OF MEA IMMUNOTHERAPY DRUGS MARKET, BY END-USER, 2017–2028 REVENUE (USD MILLION)
LIST OF FIGURE
1. RESEARCH DESIGN
2. SCOPE OF THE STUDY
3. GEOGRAPHIC SCOPE
4. CURRENCY CONSIDERATION
5. YEAR CONSIDERATION
6. MARKET ESTIMATION
7. RESEARCH METHODOLOGY
8. DATA TRIANGULATION
9. COVID-19 IMPACT ON MARKET
10. GLOBAL IMMUNOTHERAPY DRUGS MARKET ATTRACTIVENESS ANALYSIS BY TYPE
11. GLOBAL IMMUNOTHERAPY DRUGS MARKET ATTRACTIVENESS ANALYSIS BY THERAPY AREA
12. GLOBAL IMMUNOTHERAPY DRUGS MARKET ATTRACTIVENESS ANALYSIS BY END-USER
13. GLOBAL IMMUNOTHERAPY DRUGS MARKET ATTRACTIVENESS ANALYSIS BY REGION
14. GLOBAL IMMUNOTHERAPY DRUGS MARKET ATTRACTIVENESS ANALYSIS BY COUNTRY
15. GLOBAL IMMUNOTHERAPY DRUGS MARKET: DYNAMICS
16. PESTEL ANALYSIS
17. SWOT ANALYSIS
18. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY REGION
19. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY TYPE
20. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY THERAPY AREA
21. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY END-USER
22. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY NORTH AMERICA
23. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY EUROPE
24. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY ASIA PACIFIC
25. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY SOUTH AMERICA
26. GLOBAL IMMUNOTHERAPY DRUGS MARKET ANALYSIS BY MIDDLE EAST & AFRICA
27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
28. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
29. EUROPE IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
30. ASIA PACIFIC IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
31. SOUTH AMERICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
32. MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SHARE BY COMPANY (2020)
Single User
US$ 3500*** Benefits ***
1. 15% Free customization
2. Two Countries can add as per your choice
3. Two Company can add as per your choice
4. 35+ Countries
*** Services ***
1. Quarterly Industry Update for Six Months
2. One personal Research Analyst Allocate to you
3. 24*7 Research Support
4. Query will be resolve with 48 hours
Multi User
US$ 5250*** Benefits ***
1. 25% Free customization
2. Excel Data Sheet
3. Two Countries can add as per your choice
4. Two Company can add as per your choice
35+ Countries
*** Services ***
1. Client will get one updated report for a year.
2. Quarterly Industry Update for 1 Year.
3. One research analyst will allocate to you.
4. Query will be resolved within 36 hours.
24*7 Research Support.
Corporate User
US$ 7000*** Benefits ***
1. 25% Free customization
2. Excel Data Sheet
3. Two Countries can add as per your choice
4. Two Company can add as per your choice
5. 35+ Countries
*** Services ***
1. Client will get one updated report for a year.
2. Quarterly Industry Update for 1 Year.
3. One research analyst will allocate to you.
4. Query will be resolved within 36 hours.
5. 24*7 Research Support.